- Company
- Nubeqa gains flexibility with indication expansion
- by Whang, byung-woo Aug 21, 2025 06:06am
- The influence of Nubeqa (darolutamide) is rising in the market with the company expanding its indication as a treatment for metastatic hormone-sensitive prostate cancer (mHSPC). Experts believe that the drug may settle as a flexible treatment option in Korea’s market as it has broadened its path as a personalized treatment. With the approval
- Company
- Reimb of polycythemia vera drug 'BESREMi' likely in Sept
- by Eo, Yun-Ho Aug 21, 2025 06:06am
- The polycythemia vera treatment 'BESREMi' is expected to be listed on the national health insurance list. The National Health Insurance Service (NHIS) and PharmaEssentia Korea have recently reached a final agreement on the drug price negotiation for BESREMi (ropeginterferon alfa-2b). As a result, if it passes the Health Insurance Policy Re
- Company
- Viatris signs exclusive sales and distribution deal for Brid
- by Whang, byung-woo Aug 21, 2025 06:05am
- Viatris Korea announced on the 20th that it has signed an exclusive domestic promotion and distribution agreement for the general anesthesia reversal agent Bridion (Sugammadex) through a strategic partnership with MSD Korea. Under the agreement, Viatris Korea officially took over the domestic promotion and distribution of Bridion as of th
- Company
- Generics challenge the patent of mkt leading 'Rinvoq'
- by Kim, Jin-Gu Aug 21, 2025 06:05am
- The patent challenges by generics targeting AbbVie's Janus kinase (JAK) inhibitor' Rinvoq (upadacitinib)' have begun. The pharmaceutical industry anticipates that patent challenges will further expand as Rinvoq strengthens its monopolistic position in the JAK inhibitor market, which is valued at approximately KRW 62 billion annually.
- Opinion
- [Desk View] Can NHI alone cover the costs of cancer drugs?
- by Lee, Tak-Sun Aug 20, 2025 06:23am
- The reimbursement claim amount submitted for anti-cancer drugs has been increasing robustly every year. According to the '2024 Pharmaceutical Reimbursement Claims Data' published by the Health Insurance Review & Assessment Service, drug expenditure for cancer diseases in 2024 amounted to KRW 4.1372 trillion, a 7.4% increase from KRW 3.850
- Opinion
- [Reporter's View] Innovation exists in treating all diseases
- by Eo, Yun-Ho Aug 20, 2025 06:23am
- When discussing Korea’s insurance reimbursement system, the qualifier “life-threatening” has long been a source of frustration. It is no exaggeration to say that, for the pharmaceutical industry, this phrase has been the number one target for removal since the very beginning. This was the case in determining eligibility for the Risk Sh
- Company
- Expanded patent dispute over cancer drug 'Xtandi'
- by Kim, Jin-Gu Aug 20, 2025 06:22am
- The number of companies challenging the patent for Astellas' prostate cancer treatment, 'Xtandi (enzalutamide)', has expanded to six. Attention has been drawn to the fact that major pharmaceutical companies, such as Chong Kun Dang, Hanmi Pharmaceutical, and JW Pharmaceutical, have joined this latest patent challenge. According to the phar
- Policy
- MFDS's bill on stable supply of essential drugs in review
- by Lee, Jeong-Hwan Aug 20, 2025 06:22am
- A bill to add “medicines that are essential for healthcare and require stable supply” and “medicines with similar therapeutic effects with no alternative treatments” to the list of national essential medicines, thereby resolving the issue of unstable supply of medicines, is likely to pass the Health and Welfare Committee's legislative su
- InterView
- Dong-A ST launches Sterlara biosimilar Imuldosa in the US
- by Cha, Jihyun Aug 20, 2025 06:22am
- Dong-A ST (CEO: Jae-Hoon Jeong) announced on the 19th that the company has launched IMULDOSA (project name DMB-3115, active ingredient ustekinumab), a biosimilar version of Stelara, in the US through its partners, multinational pharmaceutical companies Intas Pharmaceuticals and Accord Biopharma. IMULDOSA is biosimilar version of Janssen’
- Company
- Dapa N with Forxiga's indication leads the mkt by surprise
- by Kim, Jin-Gu Aug 20, 2025 06:22am
- Prescription sales of HK inno.N's 'Dapa N,' which received transfer of Forxiga indications, have surged in the SGLT-2 inhibitor diabetes treatment market. It has risen to the top of the dapagliflozin monotherapy market. Analysis suggests that this success is attributed to Dapa N's transition in indications, including chronic heart failu
